Tyrosine Kinase Inhibitors As Novel Drugs For The Treatment Of Diabetes.

dc.creatorPrada, Patricia O
dc.creatorSaad, Mario Ja
dc.date2013-Jun
dc.date2015-11-27T13:31:45Z
dc.date2015-11-27T13:31:45Z
dc.date.accessioned2018-03-29T01:17:50Z
dc.date.available2018-03-29T01:17:50Z
dc.identifierExpert Opinion On Investigational Drugs. v. 22, n. 6, p. 751-63, 2013-Jun.
dc.identifier1744-7658
dc.identifier10.1517/13543784.2013.802768
dc.identifierhttp://www.ncbi.nlm.nih.gov/pubmed/23705634
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/200646
dc.identifier23705634
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1300879
dc.descriptionSome inhibitors of tyrosine kinase, as imatinib, erlotinib and sunitinib have antihyperglycemic effects but the mechanisms are not totally clear. It is well established that insulin resistance and beta-cell failure are hallmarks of type 2 diabetes mellitus (DM2). The present review will discuss the molecular mechanisms that account for insulin resistance and beta-cell failure in DM2, and also the effect of tyrosine kinase inhibitors in these processes. A better understanding of how these drugs improve the two most important mechanisms of DM2 associated with suggestions of clinical studies will lead to improve the treatment of this disease.
dc.description22
dc.description751-63
dc.languageeng
dc.relationExpert Opinion On Investigational Drugs
dc.relationExpert Opin Investig Drugs
dc.rightsfechado
dc.rights
dc.sourcePubMed
dc.subjectAnimals
dc.subjectClinical Trials As Topic
dc.subjectDiabetes Mellitus, Type 2
dc.subjectDrug Design
dc.subjectHumans
dc.subjectHypoglycemic Agents
dc.subjectInsulin Resistance
dc.subjectInsulin-secreting Cells
dc.subjectProtein Kinase Inhibitors
dc.subjectProtein-tyrosine Kinases
dc.titleTyrosine Kinase Inhibitors As Novel Drugs For The Treatment Of Diabetes.
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución